Biology of plasma cells

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 4 SPEC. ISS., 2005, Pages 493-507

  Chen Kiang, S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BAFF; BlyS; CD40; Cdk4; Cdk6; Cell cycle; Cyclin D; IL 6; Multiple myeloma; p18IN4c; Plasma cell; Rb; TRAIL APO2L

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD38 ANTIGEN; CD40 LIGAND; CD45 ANTIGEN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FAS ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MYC PROTEIN; PROTEIN P107; PROTEIN P130; PROTEIN P15; PROTEIN P16INK4A; PROTEIN P18; PROTEIN P19; RETINOBLASTOMA PROTEIN; SYNDECAN 1; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIBODY RESPONSE; APOPTOSIS; B LYMPHOCYTE ACTIVATION; CANCER RELAPSE; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; DISEASE ACTIVITY; HUMAN; HUMORAL IMMUNITY; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 22144462112     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.02.002     Document Type: Review

References (89)

1. R.D. Sanderson P. Lalor & M. Bernfield B lymphocytes express and lose syndecan at specific stages of differentiation Cell Regul 1 1989 27-35
2. T.B. Sneed D.J. Stanley L.A. Young & R.D. Sanderson Interleukin-6 regulates expression of the Syndecan-1 Proteoglycan on B lymphoid Cells Cell Immunol 153 1994 456-467
3. M.R. Tourigny J. Ursini-Siegel H. Lee et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells Immunity 17 2002 179-189
4. F. Ho J.E. Lortan I.C.M. MacLennan & M. Khan Distinct short-lived and long-lived antibody-producing cell populations Eur J Immunol 16 1986 1297-1301
5. R.A. Manz A. Thiel & A. Radbruch Lifetime of plasma cells in the bone marrow [letter] Nature 388 1997 133-134
6. M.K. Slifka R. Antia J.K. Whitmire & R. Ahmed Humoral immunity due to long-lived plasma cells Immunity 8 1998 363-372
7. I.C. MacLennan Germinal centers Annu Rev Immunol 12 1994 117-139
8. J. Jacob J. Przylepa C. Miller & G. Kelsoe In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. III. The kinetics of V region mutation and selection in germinal center B cells J Exp Med 178 1993 1293-1307
9. Y.J. Liu J. Zhang P.J. Lane et al. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens Eur J Immunol 21 1991 2951-2962
10. K.G. Smith A. Light G.J. Nossal & D.M. Tarlinton The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response Embo J 16 1997 2996-3006
11. A.R. Ramiro M. Jankovic T. Eisenreich et al. AID is required for c-myc/ IgH chromosome translocations in vivo Cell 118 2004 431-438
12. Y.J. Liu & J. Banchereau Regulation of B-cell commitment to plasma cells or to memory B cells Semin Immunol 9 1997 235-240
13. R. Ahmed & D. Gray Immunological memory and protective immunity: understanding their relation Science 272 1996 54-60
14. T. Hunter & J. Pines Cyclins and cancer II: Cyclin D and Cdk inhibitors come of age Cell 79 1994 573-582
15. R.A. Weinberg The retinoblastoma protein and cell cycle control Cell 81 1995 323-330
16. O. Stevaux & N.J. Dyson A revised picture of the E2F transcriptional network and RB function Curr Opin Cell Biol 14 2002 684-691
17. S.J. Sherr & J.M. Roberts CDK inhibitors: Positive and negative regulators of G1-phase progression Genes Dev 13 1999 1501-1512
18. M. Cheng P. Olivier J.A. Diehl The p21(Cip1) and p27(Kip1) CDK inhibitors are essential activators of cyclin D-dependent kinases in murine fibroblasts Embo J 18 1999 1571-1583
19. C.J. Sherr & J.M. Roberts Living with or without cyclins and cyclin-dependent kinases Genes Dev 18 2004 2699-2711
20. K. Kozar M.A. Ciemerych V.I. Rebel et al. Mouse development and cell proliferation in the absence of D-cyclins Cell 118 2004 477-491
21. D.A. Tanguay & T.C. Chiles Regulation of the catalytic subunit (p34PSK-J3/cdk4) for the major D-type cyclin in mature B lymphocytes J Immunol 156 1996 539-548
22. E.W. Lam J. Glassford L. Banerji et al. Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40 J Biol Chem 275 2000 3479-3484
23. N. Solvason W.W. Wu N. Kabra et al. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes J Exp Med 184 1996 407-417
24. D.A. Tanguay & T.C. Chiles Regulation of the catalytic subunit (p34PSK-J3Cdk4) for the major D-type cyclin in mature B cells J Immunol 156 1996 539-548
25. INK4B/MTS2-related CDK inhibitor, correlates with wild-type pRb function Genes Dev 8 1994 2939-2952
26. H. Hirai M.F. Roussel J.Y. Kato et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 Mol Cell Biol 15 5 1995 2672-2681
27. X. Huang M. Di Liberto A.F. Cunningham et al. Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1 Proc Natl Acad Sci USA 101 2004 17789-17794
28. D.S. Franklin V.L. Godfrey H. Lee et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis Genes Dev 12 1998 2899-2911
29. E. Latres M. Malumbres R. Sotillo et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis Embo J 19 2000 3496-3506
30. A. Altmeyer R.C. Simmons S. Krajewski et al. Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation Immunity 7 1997 667-677
31. M.C. Raynal Z.Y. Liu T. Hirano et al. Interleukin 6 induces secretion of IgG1 by coordinated transcriptional activation and differential mRNA accumulation Proc Natl Acad Sci USA 86 1989 8024-8028
32. Y. Natkunam X. Zhang Z. Liu & S. Chen-Kiang Simultaneous activation of Ig and Oct-2 synthesis and reduction of surface MHC class II expression by IL-6 J Immunol 153 1994 3476-3484
33. L. Morse D. Chen D. Franklin et al. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6 Immunity 6 1997 47-56
34. B.P. O'Connor M. Cascalho & R.J. Noelle Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population J Exp Med 195 2002 737-745
35. J. Ursini-Siegel W. Zhang A. Altmeyer et al. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis J Immunol 169 2002 5505-5513
36. P.H. Krammer J. Dhein H. Walczak et al. The role of AP0-1-mediated apoptosis in the immune system Immunol Rev 142 1994 175-191
37. S. Nagata Apoptosis by death factor Cell 88 1997 355-365
38. J.C. Rathmell S.E. Townsend J.C. Xu et al. Expansion or elimination of B cells in vivo: Dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor Cell 87 1996 319-329
39. J. Banchereau F. Bazan D. Blanchard et al. The CD40 antigen and its ligand Annu Rev Immunol 12 1994 881-922
40. P. Garrone E.-M. Neidhardt E. Garcia et al. Fas ligation induces apoptosis of CD40-activated human B lymphocytes J Exp Med 182 1995 1265-1273
41. T.L. Rothstein J.K.M. Wang D.J. Panka et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells Nature 374 1995 163-165
42. R.M. Pitti S.A. Marsters S. Ruppert et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J Biol Chem 271 1996 12687-12690
43. S.R. Wiley K. Schooley P.J. Smolak et al. Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673-682
44. A. Ashkenazi & V.M. Dixit Death receptors: Signaling and modulation Science 281 1998 1305-1308
45. J.L. Bodmer N. Holler S. Reynard et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8 Nat Cell Biol 2 2000 241-243
46. A. Ashkenazi R.C. Pai S. Fong et al. Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 1999 155-162
47. H. Walczak R.E. Miller K. Ariail et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 1999 157-163
48. M. Kopf H. Baumann G. Freer et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice Nature 368 1994 339-342
49. A.J. Ramsay A.J. Husband I.A. Ramshaw et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo Science 264 1994 561-563
50. D.M. Hilbert M. Kopf B.A. Mock et al. Interleukin 6 is essential for in vivo development of B lineage neoplasms J Exp Med 182 1995 243-248
51. R.P. Nordan & M. Potter A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro Science 233 1986 566-569
52. G. Jego R. Bataille & C. Pellat-Deceunynck Interleukin-6 is a growth factor for nonmalignant human plasmablasts Blood 97 2001 1817-1822
53. P.A. Moore O. Belvedere A. Orr et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator Science 285 1999 260-263
54. B. Schiemann J.L. Gommerman K. Vora et al. An essential role for BAFF in the normal development of B cells through a BCMA - independent pathway Science 293 2001 2111-2114
55. J.A. Gross J. Johnston S. Mudri et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature 404 2000 995-999
56. M. Balazs F. Martin T. Zhou & J. Kearney Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses Immunity 17 2002 341-352
57. R.K. Do E. Hatada H. Lee et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response J Exp Med 192 2000 953-964
58. E. Claudio K. Brown S. Park et al. BAFF-induced NEMO-independent processing of NF-kappaB2 in maturing B cells Nat Immunol 3 2002 958-965
59. E. Hatada R.K. Do A. Orlofsky et al. NF-kB1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kB2 p100 to p52 in quiescent mature B cells J Immunol 171 2003 761-768
60. B.P. O'Connor V.S. Raman L.D. Erickson et al. BCMA is essential for the survival of long-lived bone marrow plasma cells J Exp Med 199 2004 91-98
61. J. Shaughnessy Jr A. Gabrea Y. Qi et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma Blood 98 2001 217-223
62. F. Zhan J. Hardin B. Kordsmeier et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells Blood 99 2002 1745-1757
63. M. Chesi P.L. Bergsagel L.A. Brents et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines Blood 88 1996 674-681
64. R. Fonseca E.A. Blood M.M. Oken et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients Blood 99 2002 3735-3741
65. P. Moreau T. Facon X. Leleu et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy Blood 100 2002 1579-1583
66. S. Soverini M. Cavo C. Cellini et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Blood 102 2003 1588-1594
67. M.S. Kulkarni J.L. Daggett T.P. Bender et al. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: Ectopic p18 expression inhibits growth and induces apoptosis Leukemia 16 2002 127-134
68. T. Tasaka J. Berenson R. Vescio et al. Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma Br J Haematol 96 1997 98-102
69. M.H. Ng Y.F. Chung K.W. Lo et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma Blood 89 1997 2500-2506
70. T. Tasaka H. Asou R. Munker et al. Methylation of the p16INK4A gene in multiple myeloma Br J Haematol 101 1998 558-564
71. S. Zhang E.S. Ramsay & B.A. Mock Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1 Proc Natl Acad Sci USA 95 1998 2429-2434
72. S.L. Zhang W. DuBois E.S. Ramsay et al. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility Mol Cell Biol 21 2001 310-318
73. K.H. Shain T.H. Landowski I. Buyuksai et al. Clona variability in CD95 expression is a major determinant in Fas-mediated, but not chemotherapy-mediated apoptosis in the RPMI 8226 multiple myeloma cell line Leukemia 14 2000 830-840
74. L.F. Lincz T.X. Yeh & A. Spencer TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy Leukemia 15 2001 1650-1657
75. Q. Liu W.S. El-Deiry & Y. Gazitt Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines Exp Hematol 29 2001 962-970
76. C.S. Mitsiades S.P. Treon N. Mitsiades et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications Blood 98 2001 795-804
77. C.M. Shipman & P.I. Croucher Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/ Apo2 ligand and can function as a paracrine survival factor for human myeloma cells Cancer Res 63 2003 912-916
78. W.S. Simonet D. Lacey C.R. Dunstan et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density Cell 89 1997 309-319
79. K.P. Lam R. Kuhn & K. Rajewsky In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death [see comments] Cell 90 1997 1073-1083
80. A.C. Rawstron J.A. Fenton J. Ashcroft et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells Blood 96 2000 3880-3886
81. R. Catlett-Falcone T.H. Landowski M.M. Oshiro et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells Immunity 10 1999 105-115
82. S. Derenne B. Monica N.M. Dean et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells Blood 100 2002 194-199
83. B. Zhang V. Potyagaylo & R.G. Fenton IL-6-independent expression of Mcl-1 in human multiple myeloma Oncogene 22 2003 1848-1859
84. Y.T. Tai K. Podar N. Mitsiades et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling Blood 101 2003 2762-2769
85. M. Urashima D. Chauhan H. Uchiyama et al. CD40 Ligand triggered interleukin-6 secretion in multiple myeloma Blood 85 1995 1903-1912
86. Y.T. Tai K. Podar D. Gupta et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells Blood 99 2002 1419-1427
87. A.W. Tong B. Seamour J. Chen et al. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells Leuk Lymphoma 36 2000 543-558
88. J. Moreaux E. Legouffe E. Jourdan et al. BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone Blood 103 2004 3148-3157
89. A.J. Novak J.R. Darce B.K. Arendt et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival Blood 103 2004 689-694